Jork von Reden

Proteo, Inc., a clinical stage drug development company, intends to develop, promote, and market pharmaceuticals and other biotech products. The firm focuses on the development of anti-inflammatory treatments for rare diseases. Its proprietary product Elafin, a human protein that naturally occurs in human skin, lungs, and mammary glands. The company's product is intended for the treatment of post-surgery damage to tissue, pulmonary hypertension, serious injuries caused by accidents, cardiac infarction, and other diseases, as well as for the complications resulting from organ transplantation. It has a license and collaboration agreement with ARTES Biotechnology GmbH to produce Elafin by using the sublicensed yeast HANSENULA POLYMORPHA. The company was founded by Oliver Wiedow and Birge Bargmann on December 18, 1992 and is headquartered in Irvine, CA.

CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun provides business consulting and investment services. The private company is based in Berlin, Germany. Jork von Reden has been the CEO of the German company since 2016.